Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 219pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × crenigacestat × Clear all
NCT03502577 2024-01-08

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 1 Terminated
19 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡